Cgix

Investor Presentation
January 2015
Cancer Genetics, Inc.
Nasdaq
(CGIX)

Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 2
This presentation contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development and potential opportunities for Cancer Genetics,
Inc. products and services or Gentris, Inc. products and services, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-
looking statements. Any statements that are not historical fact (including, but not limited to, statements
that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the development and/or commercialization of
potential products, risks of cancellation of customer contracts or discontinuance of trials, risks related to
integration of the acquisitions of Gentris and BioServe and the realization of the currently anticipated
benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain
future capital, maintenance of intellectual property rights and other risks discussed in the Company's
Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014
along with other filings with the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-
looking statements.
Forward-Looking Statement

Fact Sheet
Market Cap $74.58 Mn
Stock Price $7.67 [1/9/2015]
Ticker Symbol Nasdaq: CGIX
Qtrly Revenue (yoy) 88.9%
Total Cash $30.75 Mn
Facilities
• Rutherford, NJ
• Raleigh, NC
• Hyderabad, India
• Shanghai, China
18,000 sq. ft.
28,000 sq. ft.
14,000 sq. ft.
4,000 sq. ft.
Clients
• Hospitals
• Cancer Centers
• Physician Offices
• Biotech
• Biopharma
Products 7 Launched Products
Patents 8 US Issued Patents
*Financial data as of 1/9/2015

Genomic Testing has Paved the Way for Significant
Advancements in Diagnosis & Targeted Treatment Options
Comprehensive
Report
Proprietary
Products
Focused
Oncology Lab
OUR INTEGRATED APPROACH TO MOLECULAR
TESTING BRINGS BENEFITS ACROSS THE ENTIRE
ONCOLOGY ECOSYSTEM
DIAGNOSIS
Do I have cancer and if so,
what type?
PROGNOSIS
What course will my
cancer take? What should I
expect?
THERANOSIS
What are my treatment
options? Which drug is the
best fit for me?

Proprietary Programs Drive Value for Both Biotech &
Pharma Clients and the Clinical Community
Over clinical
tests run in 2014
Patient Clinical
Testing
Contracts w. of the
pharma companies
Biopharma
Clients
collaborations w.
academic centers
Research
Collaborations

Locations in Regions with Significant Needs in Oncology
U.S. Rutherford, NJ
Raleigh, NC
India Hyderabad
China Shanghai
Locations
United States
China
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
Global – 14,090,149
cancer cases per year
$1 Bn
Biopharma
N/A
Clinical
$2.5 Bn
Biopharma
$6 Bn
Clinical
$1 Bn
Biopharma
$0.4 Bn
Clinical
Cervix
Kidney
Leukemia
Myeloma
NHL
12,829
57,729
40,090
19,243
62,540
Cervix
Kidney
Leukemia
Myeloma
NHL
61,309
67,440
64,374
12,262
42,916
India
Cervix
Kidney
Leukemia
Myeloma
NHL
122,807
10,149
32,478
7,105
23,343
cancer cases
per year

Major Drivers for our Proprietary Programs
Is there an unmet patient need?
Is it unique & can it drive an IP-ready position?
Can we leverage the existing routine sample?
Can we validate and collaborate with major
research centers?
Can it be offered as part of our Complete™
programs?
1
2
3
4
5

1.2 Mn Combined Annual New Cases Globally
Eight US Patents Awarded
7 Proprietary Diagnostic Products
Commercially Launched & In Market
Chronic Lymphocytic Leukemia 106,770 (cases/year, global)
Focus::CLL™ MatBA®-CLL/SLL
Diffuse Large B-Cell Lymphoma 142,360 (cases/year, global)
MatBA®-DLBCL
Follicular Lymphoma 62,300 (cases/year, global)
MatBA®-FL
Mantle Cell Lymphoma 17,795 (cases/year, global)
MatBA®-MCL
Kidney Cancer 340,000 (cases/year, global)
UroGenRA®-Kidney
Hematologic Cancers Urogenital Cancers
Cervical Cancer 528,000 (cases/year, global)
FHACT®
Cervical Cancer

Significant Effort & Progress in NGS Validation
Research &
Discovery
Clinical
Development
Commercial
Development
Launch &
Market Entry
Hematologic Cancers
Comprehensive Myeloid Panel [54 genes] - MiSeq
Comprehensive CLL/SLL Panel [7 genes] - MiSeq
Comprehensive Lymphoid Panel - MiSeq
Pharmacogenomics (PGx) Panel
1885 Polymorphisms – ION Torrent
Solid Tumors
Cancer Hotspot Panel [50 genes] – ION Torrent
UroGenital Cancers
Comprehensive Renal Panel - MiSeq

10Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
* Transparency Market ResearchGLOBOCAN 2012 (IARC)
Cervical Cancer: Challenges & Unmet Needs
Cervical cancer remains a worldwide public health
challenge, especially in developing countries – often
diagnosed too late.
• 85% of incidence correspond to developing countries
• Cervical cancer Dx test is estimated to reach $75 Mn globally in
2018*
1
In industrialized countries, screening programs are
VERY costly and NOT highly accurate.
• Colposcopy-guided biopsy cost ranges $600-1,200 and delays both
diagnosis and treatment
• HPV testing does not make use of somatic genome and does not
necessarily indicate presence of cancer
2
Several tests are available but the need for less
invasive and better informed treatment exists
3

FHACT®
Fits Directly into Today’s Cervical Cancer
Screening Workflow
Today, all these women are
referred for colposcopy.
Does not need
colposcopy now.
Referred for
colposcopy.
PROGRESS to a higher grade and
increased risk for cancer within 10-30
years of the infection.
REGRESS within 2
years of the infection.
FHACT®
Results:
Abnormal
FHACT®
Results:
Normal
Identify women with low grade cervical/
undetermined lesions that will progress to a
higher grade versus those that will regress.
Unmet Clinical Need
FISH-based HPV-Associated Cancer Test
Include FHACT® as additional triage before referral
for colposcopy
• No resampling
• Fewer women referred for colposcopy
• Reduced healthcare costs
CGI Solution

FISH-based HPV-Associated Cancer Test
FHACT® assesses non-random genomic alterations associated with
progression of lesion.
 Gain of 3q26 (TERC) has been detected with increasing frequency in
cervical lesions with increasing severity and is observed in about 75% of
cervical cancers.
[1-2]
 Gains of 5p15, 20q13 & chr 7 share a similar pattern of appearance in
precancerous cytology specimens by FISH (40-45%, 20q13, and 15%
respectively).
[3-4]
 Performed on remnant liquid based cytology.
 Gain at any of the FHACT® loci is detected in up to 89.5% of all
cervical cancers.
[5]
FHACT® presents the highest sensitivity on the market (4 loci).
1. Heselmeyer-Haddad K, et al. (2005). Am. J. Pathol. , 166, 1229-1238
2. Seppo A., et al. (2009) Gynecol Oncol, 114, 80-83
3. Scotto, L., et al. (2008). Mol Cancer, 7, 58.
4. Luhn P, et al. (2013). Gynecol Oncol, 130, 595-600.
5. The Cancer Genome Atlas (TCGA) (http:/cancergenome.nih.gov)
FHACT® can aid in identifying women with markers of
high grade lesions (cervical cancer)
FHACT® Loci:
 3q26 gain (red)
 5p15 gain (green)
 Cen7 (aqua)
 20q13 gain (gold)

15,720 new cases
[U.S.]
4,600 deaths
[U.S.]
Estimated
for 2014
[ACS]
 Median age at diagnosis is 65 to 68 years
 Overall median survival is 9 years
 Approximately 10% of all adult hematologic malignancies
(40% of leukemias in individuals over 65 years of age)
 Two roughly equal clinical subtypes: indolent & aggressive
Chronic Lymphocytic Leukemia (CLL)
 Risk stratification to identify patients most likely to have aggressive disease
 Therapy selection
Unmet Needs

13q
loss 12
gain 1p
gain 4p
loss 5p
loss 6q
loss 7p
loss 7p
gain
18p
gain
18q
gain
19p
gain
17p loss
11q loss
2p gain
3q gain
7q loss
8p loss
8q gain
17q
gain
18p loss
Favorable
Intermediate
Unfavorable
Favorable/
Intermediate
(no distinction)
38% of cases in our study have
a favorable prognosis falling
under "watch & wait" approach.
8% of cases with unfavorable
prognosis missed by FISH and
caught using MatBA®-CLL/SLL.
Impact on therapy selection &
clinical management of CLL
patients.
Genomic Aberrations Reported Genomic Aberrations Reported
by FISH: by MatBA®-CLL/SLL:
4 20
85%
15% 23%
39%
FISH
(Current Method)
38%
(CGI Method)
13q
loss 12
gain
17p
loss
11q
loss
Comprehensive Genomic Evaluation of CLL For Improved
Diagnosis and Prognosis

Time to First Treatment (TTFT)
Time (months)
Time (months)
Proportion
Surviving
ProportionTreatment-
Free
–GOOD(n=74)
–INTERMED(n=107)
–POOR (n=47)
–GOOD(n=74)
–INTERMED(n=107)
–POOR (n=47)
P = 0.090
P = 0.001
P < 0.001
P = 0.010
Overall Survival (OS)
Leukemia & Lymphoma, Houldsworth et al Sept 2013
Time (months)
TTFT: DFCI
ProportionTreatment-Free
P<0.001
Good(n=63)
Intermediate(n=47)
Poor (n=14)
Time (months)
OS: DFCI
ProportionSurviving
P=0.522
Good(n=63)
Intermediate(n=47)
Poor (n=14)
Time (months)
TTFT: HUMC
ProportionTreatment-Free
P=0.039
Good(n=13)
Intermediate(n=34)
Poor (n=18)
Time (months)
OS: HUMC
ProportionSurviving
P=0.044
Good(n=13)
Intermediate(n=34)
Poor (n=18)
Independent Validation Datasets
Patient Samples
[Jennifer
Brown]
[Anthony
Mato]

[Kanti Rai, Nicholas Chiorazzi,
Jacqueline Barrientos]
Significance of Current Prognostic Markers in CLL in
the B-Cell Receptor Signaling Pathway Inhibitor Era
Zydelig™ [Idelalisib (PI3K-delta)]
 FDA Approved For CLL in the relapse setting
when considering Rituximab alone
 Collaborative project in progress at CGI
 Insights will be integrated into our
CLL Complete™
IMBRUVICA™ [Ibrutinib (BTK)]
 FDA Approved for CLL with 17p loss and in the
relapse setting where two prior therapies have failed
 Genomic alterations associated with resistance
 Acquired Mutations during therapy in BTK
Gene (C481S), PLCG2 (R665W)
 Deletion of 8p
 Gain of 3q
B-CELL RECEPTOR SIGNALING
PATHWAY INHIBITORS

Solution
UroGenRA®-Kidney Can Guide Management of Patients
with Renal Masses and Appropriate Treatment Selection
Development of diagnostic algorithm
 >600 RCC malignant subtypes (in-silico: SNP)
 >100 malignant and benign renal neoplasms (in-house: aCGH & FISH)
Retrospective in-house FFPE validation (n>190) CCF
diagnostic yield
diagnostic sensitivity to distinguish benign from malignant renal neoplasms
sensitivity to distinguish malignant RCC subtypes
Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC
 Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to
surgical intervention
Men and women with renal masses often
undergo unnecessary nephrectomy for accurate
diagnosis and experience delay in treatment
Problem
UroGenRA® will detect genomic aberrations in a single assay
permitting accurate diagnosis (benign vs malignant, and malignant
subtype) guiding appropriate management and treatment strategies
[C. Magi-Galluzzi and E. Klein]
[J. Coleman and J. Durack]

 $1 M funded in 2013 to initiate Joint Venture & Another $1M in 2014
 Up to $4 M in additional funding based on project milestones
 Projects Have 12 to 30 month development horizon
 Core operations based in Rochester, MN and leverage Mayo facilities
 World class NGS facility
 Best in class bioinformatics
 Globally leading clinicians
 Immediately integrated into care
 Scientific leadership
 Disease focus and stewardship
 Commercial focus and management
 Capital access and investment
OncoSpire Genomics:
Developed by Cancer Genetics, Inc. and Mayo Clinic

Informed
Discovery
Clinical
Development
Commercial
Development
Market Entry
(with partners)
1.6 million
new cases
Lung Cancer
200,000
new cases
Multiple Myeloma
20,920
new cases
Follicular Lymphoma
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused Panels
to Become the Standard of Care in NGS-Based Oncology Management
OncoSpire Genomics:
Projects are Unique and Have High Value

Multiple Myeloma:
Setting the New Standard with a Focused NGS Panel
A comprehensive NGS-based
panel will be developed to…
To target a major unmet need growing globally:
Identifying MGUSs that need follow-up & Tx and
determining best treatments for malignancies
Provide Greater Certainty & Reduce Complexity of
Diagnosis Replaces cyto, FISH & gene expression profiling1.
2. Earlier, More Accurate, Cost-Effective Prediction of MM
Identify mutations that predict change from MGUS to MM
• 77 genes selected for panel
• DNA sequencing complete for first
60 samples
• Analysis underway comparing 3
different analytical methods to
determine best solution
• In process of optimizing clinical
laboratory design from extraction to
reporting solution
• 3 papers in the publication process
• 2 international early-access
collaborations established

Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists
• Continue to growing sales force that calls on hospitals
and regional laboratories
• Plan development of national footprint through
Expand Dx™
Biotechnology Companies
Pharmaceutical Companies
• Leverage clinical infrastructure and proprietary product
portfolio for testing services that support clinical trials
• Expand sales emphasis of Select One®
Emerging Markets
• Enhance distributor base in select emerging economies
• Partner with leading local cancer care providers and
hospitals to provide probes, arrays and clinical services
• Collaborate to create and validate microarrays and
other proprietary products
• Accelerate launch of large scale studies
Universities and Research Centers
Large, Targeted Market Opportunities
Commercialization StrategyTarget Markets

• Delivers better outcomes to community
hospitals and laboratories
• Enables community hospitals to bring
“state-of-the-art” genomic testing to
patients
• Brings personalized medicine to the
community hospital vs. just at
academic and teaching hospitals
• Allows community hospitals to keep
patients and treat them locally
• Improving care and quality is critical to
maintaining reimbursement for
community hospitals
$600,000 - $800,000 USD in Testing
Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a
Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals
& Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially
Diagnosed in Community Hospitals &
Laboratories
Unique Service Offering Developed to Enable Community
Hospitals to Improve Cancer Outcomes & Treat Patients Locally

Strong Growth in Clinical Trial Contracts with Oncology
Programs at Leading Biotech & Pharma Companies
201420132012
VALUE OF DISEASE AREA IN
BIOPHARMA TRIALS
Oncology,
41
R.A., 10Asthma/COPD, 7Vasc. Dis., 7
Prog Heart Disease, 6
Alzheimers, 6
Gaucoma, 4
Parkinsons, 4
MS, 4
HIV, 3
Other, 11

3,146
3,622
5,946
6,871 6,740
2010 2011 2012 2013 9 months,
2014
Strong History of Growth
Revenue & Clinical Services Volume Trends (Q3 Comparison 2012-2014)
Total Revenue ($Mn) Clinical Services (Test Volume)
Q3: 90% REVENUE GROWTH YEAR OVER YEAR
$1.2
$1.7
$3.2
Q3, 2012 Q3, 2013 Q3, 2014
9Months2014
9months2013
5,168

$2.52
$3.02
$4.30
$6.60
$6.16
2010 2011 2012 2013 9 months,
2014
9months2013
$4.75
3,146
3,622
5,946
6,871
6,740
2010 2011 2012 2013 9 months,
2014
9months2013
5,168
9Months2014
Strong History of Growth
Revenue & Clinical Services Volume Trends (2010 – 9 months, 2014)
Total Revenue ($Mn) Clinical Services (Test Volume)
54% FULL YEAR 2013 REVENUE GROWTH
9Months2014

Income Statement Item 9 months, 2012 9 months, 2013 9 months, 2014
Revenue $3,226 $4,755 $6,164
Gross Profit 346 1,195 805
Gross Margin (%) 11% 25% 13%
Research & Development (R&D) 1,552 1,384 3,093
Sales & Marketing (S&M) 1,050 1,275 2,738
General & Administrative (G&A) 3,475 4,259 8,231
Operating Profit (Loss) (5,731) (5,723) (13,256)
Net Income (Loss) (2,621) (9,848) (11,470)
$ in thousands
Actual 09/30/14
All Cash* $37,000
Stockholders’ Equity 38,021
$ in thousands
* All cash included $6,000 restricted to collateralize a credit line
Balance Sheet Information
Summary Statement of Operations
(9 month Comparison 2012-2014)

Clinical
Services
53%
Discovery
1%
Biopharma
46%
Customer Revenue Mix: 9 months, 2014
Medicare
13%
3rd Party
Insurers
21%
Direct Bill
19%
Clinical Services:
Multiple Customer Types Provide Diversified Revenue Mix

 2 US Patents issued for FHACT® - US Patent No. 8,865,882 and 8,883,414
 Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing capacity and improving
operational flexibility
 Launched UroGenRA®-Kidney, unique microarray for kidney cancer diagnosis in collaboration with MSKCC
 Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic demonstrated 93% diagnostic accuracy –
announced results at the AACR 105th Annual Meeting
 Launched FHACT® outside the U.S. in collaboration with the National Cancer Institute research publication
and in the U.S. as an LDT under CLIA
 Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)
 Finalized Agreement with Multiplan and Three Rivers which gave us access to 72+ million covered lives
 Launched OncoSpire Genomics – A Next Generation Sequencing Joint Venture with Mayo Clinic and
announced initial set of projects (lung cancer, multiple myeloma & follicular lymphoma)
 Expanded Dx lab services – CALR, MYD88, cobas® BRAF, & cobas® EGFR mutation analyses
 Announced Multi-Year PathAdvantage Collaboration – for FHACT® (cervical cancer)
 Partnered with AstraZeneca – CGI will provide biomarker-based Dx in Central America and the Caribbean
 Acquisitions of Gentris Corporation & Bioserve India – closed Q3, 2014
 CE mark affixed to FHACT®
 Announced Collaboration with Columbia University – for MDS and AML
Recent
Accomplishments
Upcoming Milestones
and Value Drivers
 Increasing covered lives
market access through
additional payers & health
care organizations
 Launching multi-marker NGS
panel for lymphoid
malignancies
 Additional international
agreements with life science
tools companies for DNA
Probes and product
distribution in key geographies
 MatBA® – Next phase of data
and results from Dana Farber
and HUMC studies to help
support value and
reimbursement
 Additional news on biopharma
partners & relationships
 Pursuing additional indications
for UroGenRA®-Kidney
Consistent Achievement of Milestones Expected
in Coming Quarters

Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comp. Cancer Ctr
Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis Program at
Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia University
Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular Pathology at
Columbia University
Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-
Kettering Cancer Center
Howard McLeod, PharmD
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt
Cancer Center
Andrew D. Zelenetz, M.D., Ph.D.
Chief of Lymphoma Service and Head of Molecular Hemo-Oncology
Laboratory, Department of Medicine at MSKCC
Panna Sharma President & CEO
• 15+ years as advisor to global life science & healthcare cos.
• General Manager of Oncospire Genomics, JV with Mayo Clinic
• Founded TSG Partners
• Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
• 30+ yrs in finance & deal making in the healthcare industry
• Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation
(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
• 25+ years in translational oncology research
• Published 50+ articles, 4 patents
• NIH grantee
Rob Fannon Vice President of Operations
• 10+ years operations, client management, molecular test & panel
development, and biorepository management
• Roche Molecular Systems, BioServe Biotechnologies, Ltd., Stansberry &
Associates Investment Research
John Pappajohn [Chairman] | Edmund Cannon | Raju Chaganti, Ph.D. | Geoffrey Harris
Howard McCleod, Pharm.D. | Franklyn Prendergast, M.D., Ph.D. | Panna Sharma | Michael J. Welsh M.D.
Board of Directors
Officers & Management Team
Experienced and Focused Management and Boards

• Strong and growing portfolio in molecular-focused patents for disease identification & stratification
• IP-based on unique algorithms across a broad group of chromosomal regions
• Validation of specific clinical endpoints that are associated with particular disease
outcomes or decisions
• Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms
• US Issued Patent 8,580,713
• Europe 10803548.6
• India 6657/DELNP/2012
• Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using
Fluorescence In Situ Hybridization (FISH)
• Canada 2,447,320 – Foreign Counterpart Patent
Panel for the Detection & Differentiation of Renal Cortical Neoplasms
• Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated Cancers
• PCT/US2011/050681
Methods and Tools for the Diagnosis of Female Gynecological
Cancers and Precancers
• US 61/581,350
IP Position and Detailed Global Strategy

Thank you.
For further information, please contact us at ir@cgix.com
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com
Nasdaq
(CGIX)

Cgix

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Cgix

Similar to Cgix (20)

More from RedChip Companies, Inc.

More from RedChip Companies, Inc. (20)

Recently uploaded

Recently uploaded (20)

Cgix